The content on this site is intended for healthcare professionals only
Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy...
Prof Pamela Allen - Emory University School of Medicine, Georgia, USA
22 Dec 2021
Efficacy and safety of selinexor in patients with myelofibrosis refractory or in...
Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA
20 Dec 2021
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
17 Dec 2021
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with ...
Prof Meral Beksac and Prof Roman Hájek
15 Dec 2021
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-lin...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
14 Dec 2021
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressi...
Dr Michael Bishop - University of Chicago, Chicago, USA
14 Dec 2021
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-def...
Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA
14 Dec 2021
Asciminib found to be safe and effective for heavily pretreated patients with ch...
Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA
14 Dec 2021
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first ...
Prof Andrew Wei - Monash University, Melbourne, Australia
13 Dec 2021
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL
Dr Ibrahim Aldoss - City of Hope, Duarte, USA
13 Dec 2021
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
13 Dec 2021
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes ...
Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, ...
13 Dec 2021